Antibody-Drug Conjugates (ADCs) represent a promising class of targeted therapies that combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs. By precisely delivering cytotoxic agents to tumor cells while sparing healthy tissues, ADCs have emerged as a transformative approach in cancer treatment. However, the successful development of ADCs relies heavily on the identification of high-affinity antibodies that selectively target tumor antigens.
Figure 1. ADC Antibody Screening.( Fu Z, et al.2022)
Introduction of ADC Antibody Screening
ADC Antibody Screening is the process of evaluating and selecting antibodies for their suitability to be used in Antibody-Drug Conjugates (ADCs), which are a class of targeted cancer therapies combining monoclonal antibodies with potent cytotoxic drugs. This screening process can be classified into criteria such as antibody specificity, internalization efficiency, binding affinity to the target antigen, stability, and low immunogenicity.
Our Service
Antibody Selection and Screening
Bioinformatics Analysis: Utilizing advanced bioinformatics tools to analyze antibody sequences, predict antigen binding sites, and assess potential off-target effects. We employe computational modeling and simulation techniques to design novel antibody variants with optimized binding properties.
Drug Conjugation Strategy
Conjugation Site Prediction: Predicting optimal sites for drug conjugation on antibody molecules to maximize drug loading and therapeutic efficacy.
Linker Design: Designing and evaluating linker molecules for efficient and stable drug release within target cells.
In Vitro and In Vivo Validation
Cell-Based Assays: Conducting in vitro assays to evaluate the binding specificity, internalization, and cytotoxicity of ADCs using cancer cell lines.
Animal Model Studies: Performing in vivo studies in animal models to assess the pharmacokinetics, safety profile, and therapeutic efficacy of lead ADC candidates.
Data Analysis and Interpretation
High-throughput Data Analysis: Processing and analyzing large-scale data generated from screening assays to identify lead candidates and optimize ADC design. We provide detailed structural analysis of antibody-antigen interactions and drug conjugation sites for rational design and optimization.
The Process of ADC Antibody Screening
Antibody Candidate Selection - Identification of antibody candidates from databases or experimental sources.
Structural Modeling - Generation of 3D structural models of antibody candidates and target antigens.
Docking Studies - Molecular docking studies to predict the binding interactions between antibodies and antigens.
Virtual Screening - Screening of antibody candidates against a panel of target antigens to prioritize lead candidates.
ADME/T Properties Prediction - Prediction of key pharmacokinetic and pharmacodynamic properties to guide candidate selection for further development.
Advantages of Our Services
Accelerated Screening Process
Our computational approach enables rapid screening of a large number of antibody candidates, significantly reducing time and resources.
High Accuracy and Predictivity
Our advanced algorithms and models deliver accurate predictions of binding affinities and efficacy, enhancing the selection of lead candidates.
Customized Solutions
We tailor our services to meet the specific requirements and objectives of our clients, providing personalized and flexible solutions.
At CD ComputaBio, we are dedicated to advancing drug discovery and development through innovative computational solutions. Our ADC antibody screening service represents a powerful tool for identifying high-affinity antibodies for ADC development, offering a streamlined and efficient approach to candidate selection. Contact us today to learn more about how our services can support your ADC development initiatives and propel your research towards successful therapeutic outcomes.
Reference:
- Fu Z, Li S, Han S, et al. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal transduction and targeted therapy, 2022, 7(1): 93.
* For Research Use Only.
Inquiry
